By contrast, in the recently reported FOURIER randomized controlled trial, PCSK9-inhibitor therapy that lowered LDL-C levels by about 1.5 mmol/L reduced the rates of both myocardial infarction and IS by about one-quarter over 2 years.15 This evidence concerns the gene PCSK9 and myocardial infarction.